← All indications
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.
Subtype terms (10)
More specific conditions that are subtypes of Precancerous Conditions in the MeSH hierarchy.
- Aberrant Crypt Foci
2 drugs (1 approved, 1 experimental)
- Barrett Esophagus
39 drugs (26 approved, 13 experimental)
- Erythroplasia
- Keratosis, Actinic
73 drugs (39 approved, 34 experimental)
- Leukoplakia
5 drugs approved
- Lymphomatoid Granulomatosis
80 drugs (54 approved, 26 experimental)
- Preleukemia
11 drugs (7 approved, 4 experimental)
- Smoldering Multiple Myeloma
39 drugs (29 approved, 10 experimental)
- Uterine Cervical Dysplasia
27 drugs (13 approved, 14 experimental)
- Xeroderma Pigmentosum
3 drugs approved
Drugs by status
Phase 3 trials (29)
- vitamin e
- darbepoetin alfa
- epoetin
- diindolylmethane
- eflornithine
- n-(4-hydroxyphenyl)all-trans retinamide
- ginseng
- rosuvastatin
- hypericum perforatum
- iron dextran
- T4-bacteriophage endonuclease V
- celecoxib
- acetylsalicylic acid
- sulindac
- cetuximab
- toremifene
- hepatitis a vaccine, inactivated
- ondansetron
- high-selenium yeast
- morphine
- cisplatin
- hpv 16/18 vaccine
- as04
- selenomethionine se-75
- dextromethorphan
- esomeprazole
- dalteparin
- ferrous sulfate
- selenium
Phase 2 trials (58)
- thalidomide
- aminolevulinic acid
- betathine
- bone autograft
- busulfan
- cidofovir
- valproic acid
- folic acid
- tacrolimus
- paclitaxel
- naltrexone
- hemopoietic stem cell
- aldesleukin
- photochlor
- Verpasep
- iloprost
- imiquimod
- artesunate
- oligofructose-enriched inulin
- perillyl alcohol
- peripheral blood lymphocytes
- atorvastatin
- porfimer
- ifosfamide
- methylene blue
- carboplatin
- allogeneic hematopoietic stem cells
- sirolimus
- cyclosporine
- mycophenolate
- +28 more
Phase 1 trials (27)
- cladribine
- decitabine
- methylprednisolone
- cmv-specific t-cells
- amifostine
- cilengitide
- fostemsavir
- prednisone
- fluorouracil
- ino-9012
- ganciclovir
- leucovorin
- a27.15
- monoclonal antibody e2.3
- myoinositol
- pemetrexed
- pirfenidone
- formoterol
- pyroxamide
- interleukin-12
- silicon phthalocyanine
- tetradecanoylphorbol acetate
- topotecan
- bortezomib
- budesonide
- ino-3106
- arginine
Organizations
Organization Involved with Phase 3 Indications (31)
- AstraZeneca
- Applied Genetic Technologies Corp
- GlaxoSmithKline
- GTx
- National Cancer Institute (NCI)
- University of Arizona
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- University of London
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- NRG Oncology
- Ohio State University
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- University of Michigan
- University of Rochester
- University of South Florida
- University of Toronto
- Wake Forest University
- Mayo Clinic
- University of California, Irvine
- University of California, Los Angeles
- NSABP Foundation
- University of Oxford
- University of Texas at Houston
- State University of New York, Buffalo
- University of Wisconsin
- University of Alabama, Birmingham
- +1 more
Organization Involved with Phase 2 Indications (54)
- Incyte
- Merck
- Genentech
- Pfizer
- Biogen
- LifeTime Pharmaceuticals
- The EMMES Corporation
- National Institutes of Health (NIH)
- British Columbia Cancer Agency
- National Center for Research Resources (NCRR)
- University of Pennsylvania
- AIDS Malignancy Consortium
- Baylor University
- Boston University
- Cairo University
- Cancer Biotherapy Research Group
- Case Western Reserve University
- Cancer Treatment Centers of America
- China Academy of Chinese Medical Sciences
- Emory University
- Temple University
- University of Washington
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Hoag Memorial Hospital Presbyterian
- Hoosier Cancer Research Network
- Institut Paoli-Calmettes
- Johns Hopkins University
- Northwestern University
- Oregon Health and Science University
- Rutgers University
- +24 more
Organization Involved with Phase 1 Indications (18)
- Astellas
- ISA Pharmaceuticals
- HonorHealth Research Institute
- Indiana University
- New York University
- University of Southern California
- Institute of Head and Neck Studies and Education, United Kingdom
- University of California, Berkeley
- Vanderbilt University
- Leiden University
- Institut Gustave Roussy
- YRG Care
- Department of Veteran Affairs
- Dutch Cancer Society
- Top Institute Pharma
- Frantz Medical
- Polyphenon Pharma
- Skyline Biosciences
Organization Involved with Other Experimental Indications (7)